Adenomatous Polyposis Coli Clinical Trial
Official title:
A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects With Familial Adenomatous Polyposis
The purpose of this study is to determine the effect of treatment with guselkumab in participants with familial adenomatous polyposis (FAP) on rectal/pouch polyp burden.
Familial adenomatous polyposis (FAP) is the most common polyposis syndrome. It is autosomal dominant inherited disorder characterized by early onset of hundreds to thousands of adenomatous polyps throughout colon. If left untreated, this syndrome may develop colorectal cancer (CRC). Polyps from individuals with FAP display inflammatory features associated with activation of interleukin (IL) 23/IL 17/JAK/STAT3 pathway. This inflammation is thought to contribute to further mutagenesis, culminating in tumor development. Specifically, IL-23 is linked to tumor growth and progression in CRC. Guselkumab is a human immunoglobulin monoclonal antibody directed against p19 subunit of IL-23, specifically targets IL-23 and inhibits its interaction with IL-23 receptor, inhibiting IL 23 specific intracellular signaling and subsequent cell activation and cytokine production, which result in less inflammation and reduce tumor development. The clinical hypothesis of this study is that treatment with guselkumab will reduce rectal/pouch polyp burden compared with baseline in active arms compared with placebo. The study is designed to determine if guselkumab has clinical activity in colorectum and duodenum, by reducing number of polyps over a period of 24 weeks. Participants will be randomized to 1 of 3 treatment arms (Guselkumab 100 mg [milligram] SC [subcutaneous], Guselkumab 300 mg SC, and placebo SC). Efficacy evaluations include rectal/pouch polyp burden assessment, biomarker analysis include discrete IL-23 signaling effector proteins (IL-23R, pSTAT3, Il-17A) and safety evaluations will include monitoring of adverse events, laboratory tests, vital sign measurements, and physical examination. Safety will be monitored throughout study (up to Week 60). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00585312 -
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
|
Phase 3 | |
| Completed |
NCT03095703 -
Sirolimus and Familial Adenomatous Polyposis (FAP)
|
Phase 2 | |
| Completed |
NCT05014360 -
A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
|
Phase 1 | |
| Completed |
NCT01604564 -
Registry With Information About Colitis Ulcerosa and Familial Adenomatous Polyposis Patients
|
||
| Recruiting |
NCT05919264 -
FOG-001 in Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02113202 -
Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW
|
Phase 1 | |
| Withdrawn |
NCT03027401 -
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
|
||
| Recruiting |
NCT06435533 -
Cold Atmospheric Plasma for the Endoscopic Treatment of Duodenal Polyps in Patients With Familial Adenomatous Polyposis
|
N/A | |
| Terminated |
NCT00140894 -
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
|
Phase 4 | |
| Active, not recruiting |
NCT01187901 -
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
|
Phase 2 | |
| Recruiting |
NCT00319007 -
Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis
|
Phase 2 | |
| No longer available |
NCT04948398 -
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
|